Hologic, Inc. (NASDAQ:HOLX) Given Consensus Recommendation of “Hold” by Analysts

Shares of Hologic, Inc. (NASDAQ:HOLX) have been assigned an average rating of “Hold” from the nine brokerages that are currently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $87.00.

A number of equities analysts recently commented on HOLX shares. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and raised their price target for the stock from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Needham & Company LLC restated a “buy” rating and set a $90.00 target price on shares of Hologic in a research report on Wednesday, April 10th. StockNews.com lowered shares of Hologic from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. UBS Group increased their price target on shares of Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, February 2nd. Finally, Evercore ISI increased their price target on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th.

Insider Activity at Hologic

In other news, CFO Karleen Marie Oberton sold 14,940 shares of the firm’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the completion of the transaction, the chief financial officer now owns 103,916 shares of the company’s stock, valued at $7,793,700. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Karleen Marie Oberton sold 14,940 shares of the firm’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the completion of the transaction, the chief financial officer now owns 103,916 shares of the company’s stock, valued at $7,793,700. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. Insiders sold a total of 32,846 shares of company stock valued at $2,473,443 in the last quarter. Insiders own 1.75% of the company’s stock.

Institutional Investors Weigh In On Hologic

Large investors have recently modified their holdings of the company. McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Hologic during the fourth quarter worth $27,000. Venturi Wealth Management LLC acquired a new stake in shares of Hologic during the third quarter worth $29,000. NBC Securities Inc. acquired a new stake in shares of Hologic during the third quarter worth $33,000. Bartlett & CO. Wealth Management LLC acquired a new stake in shares of Hologic during the fourth quarter worth $33,000. Finally, Deseret Mutual Benefit Administrators increased its position in shares of Hologic by 42.2% during the third quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 155 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Up 0.3 %

HOLX stock opened at $77.54 on Tuesday. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $18.20 billion, a PE ratio of 36.75, a PEG ratio of 2.62 and a beta of 1.00. Hologic has a 1-year low of $64.02 and a 1-year high of $87.88. The business’s 50 day simple moving average is $75.64 and its 200 day simple moving average is $72.42.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The firm’s revenue was down 5.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.07 EPS. As a group, research analysts anticipate that Hologic will post 4.02 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.